20 completed, 2 unknown, 1 recruiting, 1 terminated. 25 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 25 | Completed 20, Unknown 2, Recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 2 | 3 | Completed 1, Terminated 1, Withdrawn 1 |
Follow Basiliximab: new trials by email Literature Review of Basiliximab trials Research Report on Basiliximab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Induction in Sensitized Kidney Transplant Recipients Without Pre-existing Donor-specific antiboDies Rabbit Anti thymocyte globulin (rATG), Basiliximab - Renal Transplant Rejection, Induction Therapy | Phase 3 | Recruiting | University Hospital, Tours | 244 | 2023-11-07 | 2026-06-18 |
| Efficacy and Safety of UC-MSCs for the Treatment of Steroid-resistant aGVHD Following Allo-HSCT UC-MSC, Anti-CD25 mAb - Graft Vs Host Disease | Phase 3 | Completed | Peking University People's Hospital | 130 | 2021-02-01 | 2023-06-01 |
| 12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients Everolimus, Tacrolimus, Cyclosporin A - Kidney Transplantation, Renal Transplantation | Phase 3 | Completed | Novartis Pharmaceuticals | 612 | 2012-12-27 | 2017-05-01 |
| A National Multi-center Randomized, Open Label Study to Evaluate Efficacy and Safety of Everolimus With EC-MPS Compared to Standard Treatment Combination Tacrolimus and EC-MPS in de Novo Liver Transplant Recipients tacrolimus, everolimus, Basiliximab - Liver Transplantation | Phase 3 | Completed | Novartis Pharmaceuticals | 188 | 2012-12-01 | 2016-04-27 |
| Thymoglobulin Induction in Kidney Transplant Recipients antithymocyte globulin, Basiliximab - Kidney Transplantation, Ischemia-Reperfusion Injury | Phase 3 | Unknown | University of Oxford | 40 | 2011-01-01 | 2010-11-11 |
| Campath, Calcineurin Inhibitor Reduction and Chronic Allograft Nephropathy Alemtuzumab, Basiliximab, Sirolimus - Kidney Transplantation | Phase 2 / Phase 3 | Completed | University of Oxford | 852 | 2010-09-01 | 2020-04-02 |
| Phase 3b Study to Evaluate Advagraf in Combination With Mycophenolate Mofetil and Basiliximab in Liver Transplantation Advagraf, Mycophenolate Mofetil, Basiliximab - Liver Transplantation | Phase 3 | Completed | Astellas Pharma Inc | 893 | 2009-09-30 | 2024-11-01 |
| Progression of Renal Interstitial Fibrosis / Tubular Atrophy (IF/TA) According to Epithelial-mesenchymal Transition (EMT) and Immunosuppressive Regimen (Everolimus Based Versus CNI Based) in de Novo Renal Transplant Recipients Certican®, Neoral, Myfortic - Renal Interstitial Fibrosis | Phase 3 | Completed | Novartis Pharmaceuticals | 194 | 2009-09-01 | 2014-03-18 |
| Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal Allografts tacrolimus, Simulect, Cellcept - Kidney Transplantation | Phase 3 | Completed | Astellas Pharma Inc | 281 | 2009-08-17 | 2024-11-01 |
| Study to Evaluate the Safety of Chronic Administration of Simulect to Subjects Receiving a First Kidney Transplant basiliximab - End Stage Renal Disease | Phase 2 / Phase 3 | Terminated | Drexel University College of Medicine | 5 | 2009-05-01 | 2015-02-10 |
| CNI-free de Novo Protocol in Patients Undergoing Liver Transplantation With Renal Impairment anti-CD 25 mAb, Sirolimus, MMF - End Stage Liver Disease, Impaired Renal Function | Phase 3 | Completed | University of Regensburg | 27 | 2008-12-01 | 2014-12-16 |
| Concentration Controlled Everolimus With Reduced Dose Cyclosporine Versus Mycophenolate Mofetil With Standard Dose Cyclosporine in de Novo Renal Transplant Adult Recipients Treated With Basiliximab and Corticosteroids Everolimus, Mycophenolate mofetil (MMF), Basiliximab - Kidney Transplantation | Phase 3 | Completed | Novartis | 122 | 2008-02-01 | 2013-06-21 |
| Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol Islets of Langerhans transplantation - Type 1 Diabetes Mellitus | Phase 3 | Completed | CellTrans Inc. | 21 | 2007-09-05 | 2026-11-04 |
| Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Calcineurin Inhibitor (CNI)-Free Regimen and a CNI-low Dose Regimen Everolimus, Myfortic, Sandimmun Optoral - Kidney Transplantation | Phase 3 | Completed | Novartis Pharmaceuticals | 802 | 2007-07-01 | 2017-01-18 |
| EXTEND Protocol for Transplanted Patient to Evaluate Kidney Function basiliximab - Kidney Transplant | Phase 3 | Unknown | McGill University Health Centre/Research Institute of the McGill University Health Centre | 50 | 2007-04-01 | 2007-04-12 |
| Efficacy of Islet After Kidney Transplantation Islet transplantation, Antithymocyte Globulin, Daclizumab or Basiliximab - Type 1 Diabetes Mellitus | Phase 3 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 24 | 2007-01-01 | 2017-10-20 |
| Islet Transplantation in Type 1 Diabetes Allogeneic Pancreatic Islet Cells, Antithymocyte Globulin, Sirolimus - Type 1 Diabetes Mellitus | Phase 3 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 48 | 2006-10-01 | 2019-07-17 |
| Preservation of Renal Function in Liver Transplant Recipients With Certican Therapy everolimus, basiliximab, CNI - Liver Transplantation | Phase 3 | Completed | Novartis Pharmaceuticals | 276 | 2006-08-01 | 2015-02-06 |
| Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients Everolimus, Mycophenolic Acid (MPA), Cyclosporine A (CsA) - Kidney Transplantation, Graft Rejection | Phase 3 | Completed | Novartis | 833 | 2005-10-01 | 2011-05-10 |
| Everolimus in a Cyclosporine Microemulsion-free Regimen Compared to a Low-dose Cyclosporine Microemulsion Regimen, in de Novo Kidney Transplant Patients Everolimus (Certican), Cyclosporine (Neoral), Steroid - Organ Transplantation, Renal Transplantation | Phase 3 | Completed | Novartis | 114 | 2005-07-01 | 2018-08-09 |
Showing 20 of 25. Sign in to see all of them.
Diabetes Mellitus, Type 1 (3) · Rejection, Psychology (3) · Graft vs Host Disease (2) · Hypoglycemia (2) · Emphysema (1) · End Stage Liver Disease (1) · Hepatitis C (1) · Infections (1) · Kidney Failure, Chronic (1) · Pulmonary Disease, Chronic Obstructive (1) · Renal Insufficiency (1) · Reperfusion Injury (1)
Novartis (6) · Novartis Pharmaceuticals (5) · Astellas Pharma Inc (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · University of Oxford (2) · CellTrans Inc. (1) · Drexel University College of Medicine (1) · Genentech, Inc. (1) · McGill University Health Centre/Research Institute of the McGill University Health Centre (1) · Peking University People's Hospital (1) · University Health Network, Toronto (1) · University Hospital, Tours (1) · University of Regensburg (1)
Canada (6) · Germany (6) · France (5) · United States (5) · Switzerland (3) · United Kingdom (3) · Austria (2) · Argentina (1) · Belarus (1) · Belgium (1) · Brazil (1) · China (1) · Colombia (1) · Czechia (1) · Finland (1)
Ali Naji, PhD (1) · Andreas A Schnitzbauer, MD (1) · Andrew Posselt, MD, PhD (1) · Bernhard Hering, MD (1) · Camillo Ricordi, MD (1) · Cecilia Chaparro, MD (1) · Colin Baigent (1) · Hans J Schlitt, MD (1) · James F. Markmann, MD, PhD (1) · James Shapiro, MD, PhD (1) · Jose Oberholzer, MD (1)
PMID 39382091, PMID 19005405, PMID 19005406, PMID 20840760, PMID 23230975, PMID 23422495, PMID 23438305, PMID 23630300, PMID 23641902, PMID 23866828, PMID 25078310, PMID 25629445, PMID 26018348, PMID 26888217, PMID 27208344, PMID 27465220, PMID 28605781, PMID 29226570, PMID 29563196, PMID 29779835, PMID 30231851, PMID 30582281, PMID 30903722, PMID 31530561, PMID 38413930, PMID 38993854, PMID 39082471, PMID 39735417, PMID 39739990
2008 (2), 2009 (2), 2005 (1)